مقايسه سطح سرمي كموكين Gro-alpha در بيماران ديابتي نوع 2 و افراد سالم

The Comparison of the Level of Serum Concentration of Gro-A Chemokine in Diabetic Type-2 Patients and Healthy People: A Short Communication

Background and Objectives: Type-2 diabetes mellitus is the most common type of diabetes, but the main cause of which is yet to be identified. One of the symptoms of diabetes is delay in healing of the wounds. Chemokines play key roles in both the regulation of immune system functions and regeneration of the damaged tissues. Growth-regulatory oncogen (Gro) is an angiogenesis chemokine. Therefore, we dicided to compare the serum level of Gro-o chemokine in diabetic patients and healthy people. Material and Methods: In this descriptive study respondents were 45 diabetic and 45 healthy people referred to Ali Ibn Abitaleb hospital in Rafsanjan. The level of Gro-o was detected by ELISA. Data were analysed using SPSS version 12. T-test was used to compare continuous data. Results: Although there were differences between diabetic and healthy people based on the serum level of Groa chemokine, this difference was not significant. Conclusion: Based on our results, it can be concluded that diabetic patients are unable to produce enough Gro-ce and this can be the reason for the delay in healing of the wounds. Furthermore, to assess the role of this chemokine more number of samples are needed for examination.